Through its Matrix subsidiary, Mylan is one of the world’s largest suppliers of the active pharmaceutical ingredients used to make generic antiretroviral (ARV) products, which treat people living with HIV/AIDS. The company also maintains an impressive portfolio of finished dosage forms of ARVs, including pediatric therapies. The hallmark of Mylan’s ARV franchise to date is affordability, as it has continually and significantly reduced drug costs. As a result, the company’s ARV products are helping nearly one-third of all people receiving treatment today for HIV/AIDS in the developing world. The company intends to build on this achievement by introducing innovations that expand people’s access to ARV medications and related resources. Click the images below to view, download or print a copy of our ARV Brochure as well as information on the importance of early treatment in the prevention of HIV/AIDS.